Glucagon like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to manage type 2 diabetes mellitus (T2DM) due to their ability to enhance glucose-dependent insulin secretion, reduce glucagon secretion, increase β-cell mass, delay gastric emptying and increase satiety13–16. This evidence concerns the gene GCG and diabetes mellitus.